Supect    (Radotinib)        CML      Chronic Myeloid Leukemia

       
       The drug called Supect and made from radotinib (IY5511) by Il-Yang Pharmaceutical Co. in South Korea is the first anti-leukemia drug made in Asia. 
       This drug can also be administered to people who are non-responsive or resistant to current drugs as imatinib, nilotinib and dasatinib.
        ''A research team at Seoul St. Mary's Hospital's hematopoetic stem cell transplant center, led by professor Kim Dong-Wook, administered the new medicine, named IY5511, to 22 chronic myeloid leukemia patients from July 2008''...    Extract from Youhp 

           

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial
December 10, 2012, ASH 2012

Korean Pharmaceutical Company Develops New Leukemia Treatment
January 6, 2012, Arirang

Sale of new drug for myelogenous leukemia approved
January 5, 2012, Korea Times

S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, OANA News

S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, Yonhap News Agency

Radotinib approved in South Korea for CML
January 5, 2012, Biotech strategy blog

New S. Korean Leukemia Drug Begins Final Phase of Clinical Trials
August 12, 2011, KBS World

New Leukemia Drug Shows Promise
July 30, 2009, Korea Times

New Leukemia Drug developed by Korean Drug Maker
July 29, 2009, MySpace.com

---

Clinical Trial Centers
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

'